132
Views
14
CrossRef citations to date
0
Altmetric
Review

T regulatory cells as an immunotherapy for transplantation

, &
Pages 315-324 | Published online: 21 Mar 2006

Bibliography

  • YU X, CARPENTER P, ANASETTI C: Advances in transplantation tolerance. Lancet (2001) 357(9272):1959-1963.
  • WOOD KJ, SAKAGUCHI S: Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. (2003) 3(3):199-210.
  • SAKAGUCHI S, SAKAGUCHI N, SHIMIZU J et al.: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. (2001) 182:18-32.
  • TAKAHASHI T, KUNIYASU Y, TODA M et al.: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. (1998) 10(12):1969-1980.
  • LECHLER RI, GARDEN OA, TURKA LA: The complementary roles of deletion and regulation in transplantation tolerance. Nat. Rev. Immunol. (2003) 3(2):147-158.
  • ALBERT MH, YU XZ, MARTIN PJ, ANASETTI C: Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. Blood (2005) 105(3):1355-1361.
  • WELLS AD, LI XC, LI Y et al.: Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. (1999) 5(11):1303-1307.
  • TAYLOR PA, PANOSKALTSIS-MORTARI A, FREEMAN GJ et al.: Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood (2005) 105(8):3372-3380.
  • TAYLOR PA, PANOSKALTSIS-MORTARI A, NOELLE RJ, BLAZAR BR: Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody. J. Immunol. (2000) 164(2):612-622.
  • YU XZ, MARTIN PJ, ANASETTI C: Role of CD28 in acute graft-versus-host disease. Blood (1998) 92(8):2963-2970.
  • BLAZAR BR, TAYLOR PA, PANOSKALTSIS-MORTARI A, SHARPE AH, VALLERA DA: Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. (1999) 162(11):6368-6377.
  • QIN S, COBBOLD SP, POPE H et al.: ‘Infectious’ transplantation tolerance. Science (1993) 259(5097):974-977.
  • YIN D, FATHMAN CG: CD4-positive suppressor cells block allotransplant rejection. J. Immunol. (1995) 154(12):6339-6345.
  • CHEN ZK, COBBOLD SP, WALDMANN H, METCALFE S: Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation (1996) 62(9):1200-1206.
  • LIU Z, TUGULEA S, CORTESINI R, SUCIU-FOCA N: Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells. Int. Immunol. (1998) 10(6):775-783.
  • CHANG CC, CIUBOTARIU R, MANAVALAN JS et al.: Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol. (2002) 3(3):237-243.
  • SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. (1995) 155(3):1151-1164.
  • COHEN JL, TRENADO A, VASEY D, KLATZMANN D, SALOMON BL: CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J. Exp. Med. (2002) 196(3):401-406.
  • ITOH M, TAKAHASHI T, SAKAGUCHI N et al.: Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. (1999) 162(9):5317-5326.
  • ALBERT MH, LIU Y, ANASETTI C, YU XZ: Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur. J. Immunol. (2005) 35(9):2598-2607.
  • HOFFMANN P, ERMANN J, EDINGER M, FATHMAN CG, STROBER S: Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. (2002) 196(3):389-399.
  • GROUX H, O’GARRA A, BIGLER M et al.: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389(6652):737-742.
  • LEVINGS MK, SANGREGORIO R, GALBIATI F et al.: IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. (2001) 166(9):5530-5539.
  • WEINER HL: Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. (2001) 182:207-214.
  • ZHANG J, GAO JX, SALOJIN K et al.: Regulation of fas ligand expression during activation-induced cell death in T cells by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. J. Exp. Med. (2000) 191(6):1017-1030.
  • SEINO KI, FUKAO K, MURAMOTO K et al.: Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. USA (2001) 98(5):2577-2581.
  • SAKAGUCHI S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. (2005) 6(4):345-352.
  • KUNIYASU Y, TAKAHASHI T, ITOH M et al.: Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. (2000) 12(8):1145-1155.
  • DARRASSE-JEZE G, MARODON G, SALOMON BL, CATALA M, KLATZMANN D: Ontogeny of CD4+CD25+ regulatory/suppressor T cells in human fetuses. Blood (2005) 105(12):4715-4721.
  • ASANO M, TODA M, SAKAGUCHI N, SAKAGUCHI S: Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. (1996) 184(2):387-396.
  • FONTENOT JD, RUDENSKY AY: A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. (2005) 6(4):331-337.
  • LIANG S, ALARD P, ZHAO Y et al.: Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. (2005) 201(1):127-137.
  • KRETSCHMER K, APOSTOLOU I, HAWIGER D et al.: Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. (2005) 6(12):1219-1227.
  • SUZUKI H, KUNDIG TM, FURLONGER C et al.: Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science (1995) 268(5216):1472-1476.
  • KRAMER S, SCHIMPL A, HUNIG T: Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J. Exp. Med. (1995) 182(6):1769-1776.
  • SETOGUCHI R, HORI S, TAKAHASHI T, SAKAGUCHI S: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. (2005) 201(5):723-735.
  • D’CRUZ LM, KLEIN L: Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. (2005) 6(11):1152-1159.
  • FONTENOT JD, RASMUSSEN JP, GAVIN MA, RUDENSKY AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. (2005) 6(11):1142-1151.
  • TAI X, COWAN M, FEIGENBAUM L, SINGER A: CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin-2. Nat. Immunol. (2005) 6(2):152-162.
  • TANG Q, BODEN EK, HENRIKSEN KJ et al.: Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur. J. Immunol. (2004) 34(11):2996-3005.
  • SERRA P, AMRANI A, YAMANOUCHI J et al.: CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity (2003) 19(6):877-889.
  • SALOMON B, LENSCHOW DJ, RHEE L et al.: B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 12(4):431-440.
  • HERMAN AE, FREEMAN GJ, MATHIS D, BENOIST C: CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. (2004) 199(11):1479-1489.
  • GHIRINGHELLI F, MENARD C, TERME M et al.: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. (2005) 202(8):1075-1085.
  • LIM HW, HILLSAMER P, BANHAM AH, KIM CH: Cutting edge: Direct suppression of B cells by CD4+ CD25+ regulatory T cells. J. Immunol. (2005) 175(7):4180-4183.
  • THORNTON AM, SHEVACH EM: Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. (2000) 164(1):183-190.
  • SHIMIZU J, YAMAZAKI S, TAKAHASHI T, ISHIDA Y, SAKAGUCHI S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. (2002) 3(2):135-142.
  • TAKAHASHI T, TAGAMI T, YAMAZAKI S et al.: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen-4. J. Exp. Med. (2000) 192(2):303-310.
  • HORI S, NOMURA T, SAKAGUCHI S: Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299(5609):1057-1061.
  • FONTENOT JD, GAVIN MA, RUDENSKY AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. (2003) 4(4):330-336.
  • KHATTRI R, COX T, YASAYKO SA, RAMSDELL F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. (2003) 4(4):337-342.
  • BENNETT CL, OCHS HD: IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr. Opin. Pediatr. (2001) 13(6):533-538.
  • THORNTON AM, SHEVACH EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. (1998) 188(2):287-296.
  • KINGSLEY CI, KARIM M, BUSHELL AR, WOOD KJ: CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J. Immunol. (2002) 168(3):1080-1086.
  • TANG Q, ADAMS JY, TOOLEY AJ et al.: Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. (2006) 7(1):83-92.
  • WALKER LS, CHODOS A, EGGENA M, DOOMS H, ABBAS AK: Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J. Exp. Med. (2003) 198(2):249-258.
  • HOFFMANN P, EDER R, KUNZ-SCHUGHART LA, ANDREESEN R, EDINGER M: Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood (2004) 104(3):895-903.
  • TANG Q, HENRIKSEN KJ, BI M et al.: In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. (2004) 199(11):1455-1465.
  • BLUESTONE JA, ABBAS AK: Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. (2003) 3(3):253-257.
  • TARBELL KV, YAMAZAKI S, OLSON K, TOY P, STEINMAN RM: CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. (2004) 199(11):1467-1477.
  • RONCAROLO MG, LEVINGS MK, TRAVERSARI C: Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. (2001) 193(2):F5-F9.
  • HORWITZ DA, ZHENG SG, GRAY JD et al.: Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin. Immunol. (2004) 16(2):135-143.
  • MARTIN PJ: Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J. Exp. Med. (1993) 178(2):703-712.
  • TAYLOR PA, LEES CJ, BLAZAR BR: The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 99(10):3493-3499.
  • ERMANN J, HOFFMANN P, EDINGER M et al.: Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood (2005) 105(5):2220-2226.
  • TAYLOR PA, PANOSKALTSIS-MORTARI A, SWEDIN JM et al.: L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 104(12):3804-3812.
  • WYSOCKI CA, JIANG Q, PANOSKALTSIS-MORTARI A et al.: Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood (2005) 106(9):3300-3307.
  • JOFFRE O, GORSSE N, ROMAGNOLI P, HUDRISIER D, VAN MEERWIJK JP: Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes. Blood (2004) 103(11):4216-4221.
  • EDINGER M, HOFFMANN P, ERMANN J et al.: CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. (2003) 9(9):1144-1150.
  • JONES SC, MURPHY GF, KORNGOLD R: Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol. Blood Marrow Transplant. (2003) 9(4):243-256.
  • TRENADO A, CHARLOTTE F, FISSON S et al.: Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. (2003) 112(11):1688-1696.
  • MIURA Y, THOBURN CJ, BRIGHT EC et al.: Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 104(7):2187-2193.
  • ZORN E, KIM HT, LEE SJ et al.: Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood (2005) 106(8):2903-2911.
  • RIEGER K, LODDENKEMPER C, MAUL J et al.: Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood (2006) 107(4):1717-1723.
  • CLARK FJ, GREGG R, PIPER K et al.: Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood (2004) 103(6):2410-2416.
  • BLUESTONE JA: Regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol. (2005) 5(4):343-349.
  • LEONG LY, QIN S, COBBOLD SP, WALDMANN H: Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression. Eur. J. Immunol. (1992) 22(11):2825-2830.
  • SYKES M, SACHS DH: Bone marrow transplantation as a means of inducing tolerance. Semin. Immunol. (1990) 2(6):401-417.
  • HARA M, KINGSLEY CI, NIIMI M et al.: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. (2001) 166(6):3789-3796.
  • GRACA L, COBBOLD SP, WALDMANN H: Identification of regulatory T cells in tolerated allografts. J. Exp. Med. (2002) 195(12):1641-1646.
  • ZHENG XX, SANCHEZ-FUEYO A, SHO M et al.: Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity (2003) 19(4):503-514.
  • SCHENK S, KISH DD, HE C et al.: Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J. Immunol. (2005) 174(6):3741-3748.
  • YOSHIZAWA A, ITO A, LI Y et al.: The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant. Proc. (2005) 37(1):37-39.
  • MELONI F, VITULO P, BIANCO AM et al.: Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation (2004) 77(5):762-766.
  • KARIM M, FENG G, WOOD KJ, BUSHELL AR: CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood (2005) 105(12):4871-4877.
  • GRACA L, LE MOINE A, LIN CY et al.: Donor-specific transplantation tolerance: the paradoxical behavior of CD4+CD25+ T cells. Proc. Natl. Acad. Sci. USA (2004) 101(27):10122-10126.
  • SANCHEZ-FUEYO A, SANDNER S, HABICHT A et al.: Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J. Immunol. (2006) 176(1):329-334.
  • BUSHELL A, JONES E, GALLIMORE A, WOOD K: The generation of CD25+ CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen. J. Immunol. (2005) 174(6):3290-3297.
  • CHAI JG, XUE SA, COE D et al.: Regulatory T cells, derived from naive CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation (2005) 79(10):1310-1316.
  • LI XC, STROM TB, TURKA LA, WELLS AD: T cell death and transplantation tolerance. Immunity (2001) 14(4):407-416.
  • KAWAI M, KITADE H, MATHIEU C, WAER M, PIRENNE J: Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation (2005) 79(9):1073-1077.
  • COENEN JJ, KOENEN HJ, RIJSSEN EV, HILBRANDS LB, JOOSTEN I: Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood (2005) 107(3):1018-1023.
  • BATTAGLIA M, STABILINI A, RONCAROLO MG: Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 105(12):4743-4748.
  • GAME DS, HERNANDEZ-FUENTES MP, LECHLER RI: Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am. J. Transplant. (2005) 5(3):454-464.
  • GREGORI S, CASORATI M, AMUCHASTEGUI S et al.: Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. (2001) 167(4):1945-1953.
  • HEROLD KC, HAGOPIAN W, AUGER JA et al.: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. (2002) 346(22):1692-1698.
  • CARPENTER PA, APPELBAUM FR, COREY L et al.: A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood (2002) 99(8):2712-2719.
  • OPELZ G: Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study. Transplant. Proc. (1997) 29(1-2):617-619.
  • KOHM AP, WILLIAMS JS, BICKFORD AL et al.: Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. (2005) 174(8):4525-4534.
  • KESSELS HW, WOLKERS MC, VAN DEN BOOM MD, VAN DER VALK MA, SCHUMACHER TN: Immunotherapy through TCR gene transfer. Nat. Immunol. (2001) 2(10):957-961.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.